Skip to Content

M R7 (Rabeprazole Sodium Delayed-Release 20 mg)

Pill with imprint M R7 is Beige, Round and has been identified as Rabeprazole sodium delayed-release 20 mg. It is supplied by Mylan Pharmaceuticals Inc..

Rabeprazole is used in the treatment of gerd; barrett's esophagus; duodenal ulcer; erosive esophagitis; duodenal ulcer prophylaxis (and more), and belongs to the drug class proton pump inhibitors. There is no proven risk in humans during pregnancy. Rabeprazole 20 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for M R7

Rabeprazole sodium delayed-release 20 mg M R7
Rabeprazole sodium delayed-release 20 mg M R7  Front
Rabeprazole sodium delayed-release 20 mg M R7  Back
Rabeprazole sodium delayed-release 20 mg M R7

Rabeprazole sodium delayed-release

Imprint:
M R7
Strength:
20 mg
Color:
Beige
Shape:
Round
Availability:
Prescription only
Drug Class:
Proton pump inhibitors
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Mylan Pharmaceuticals Inc.
National Drug Code (NDC):
00378-6709

Get help with Imprint Code FAQs.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide